The Motley Fool

Results: How CSL Limited’s (ASX:CSL) profits jumped 29% this year

The CSL Limited (ASX: CSL) share price rose 2% to $205.39 following the announcement of bumper results this morning. For the full year to 30 June 2018, CSL reported 15% growth in revenue to US$7.6 billion (all figures in USD) and 29% growth in net profit after tax to $1.73 billion.

This equates to diluted earnings per share of $3.81 and dividends per share of $1.72, unfranked. CSL ended the year with approximately $3.5 billion in net debt. Research development expenditure fell slightly to just below 10% of revenue, with $702 million spent on R&D in the year.

Much of the growth was driven by wider margins, with earnings before interest and tax (EBIT) margins rising from 25% to 30%. CSL’s return on invested capital (ROIC) improved from 24.5% to 25.9%.

During the year CSL also delivered growth across almost every aspect of its business, with CSL Behring delivering sales growth in every region:

Source: Company presentation

Management also reported strong growth in the numbers of plasma collection centres being opened during the year. Plasma collection is a good leading indicator of growth in CSL’s blood products – CSL collects the plasma to turn it into medical products for use in patients.

Recently acquired vaccine business Seqirus also delivered strong growth, growing its overall sales despite sharp falls in emerging markets and Asia Pacific:

Source: Company presentation

In its outlook for financial year 2019 (FY19) CSL guided for above-market collections growth, which means it will be attempting to grow market share in plasma collection. CSL noted that supply of plasma remains a limiting factor for the industry.

Management also guided for approximately $1.2 billion of capital expenditure as well as a ~$200 million increase in R&D expenditure to bring research spending up to 10% of revenue.

CSL has several exciting products in Phase 3 trials this year and appears set to grow for the near future.

At $200 a share it’s not cheap by any measure, but I wouldn’t be inclined to sell any shares.

NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.


Motley Fool contributor Sean O'Neill has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.